Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A. Glimelius B, et al. Among authors: heikkila r. Ann Oncol. 2008 May;19(5):909-14. doi: 10.1093/annonc/mdm588. Epub 2008 Jan 21. Ann Oncol. 2008. PMID: 18209013 Free article. Clinical Trial.
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Cunningham D, et al. Among authors: heikkila r. Lancet. 1998 Oct 31;352(9138):1413-8. doi: 10.1016/S0140-6736(98)02309-5. Lancet. 1998. PMID: 9807987 Clinical Trial.
Chemotherapy in end-of-life care.
Heikkilä R, Kaasa S. Heikkilä R, et al. Ann Oncol. 2017 Apr 1;28(4):684-685. doi: 10.1093/annonc/mdx039. Ann Oncol. 2017. PMID: 28327919 Free article. No abstract available.
The c-erbB-2 protein in primary and metastatic breast carcinomas.
Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K. Nesland JM, et al. Among authors: heikkila r. Ultrastruct Pathol. 1991 May-Jun;15(3):281-9. doi: 10.3109/01913129109021890. Ultrastruct Pathol. 1991. PMID: 1678562
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C. Tynninen O, et al. Among authors: heikkila r. Br J Cancer. 2002 Jun 17;86(12):1905-8. doi: 10.1038/sj.bjc.6600325. Br J Cancer. 2002. PMID: 12085184 Free PMC article. Clinical Trial.
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Achard V, et al. Among authors: heikkila r. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. Radiother Oncol. 2022. PMID: 35476942 Free article. Clinical Trial.
240 results